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Abstract
Background: Gastric emptying is impaired in patients with gastroparesis whereas it is either unchanged or accelerated
in obese individuals. The goal of the current study was to identify changes in gene expression in the stomach muscularis
that may be contributing to altered gastric motility in idiopathic gastroparesis and obesity.
Methods: Quantitative real time RT-PCR and whole transcriptome sequencing were used to compare the transcriptomes
of lean individuals, obese individuals and either lean or obese individuals with idiopathic gastroparesis.
Results: Obesity leads to an increase in mRNAs associated with muscle contractility whereas idiopathic gastroparesis
leads to a decrease in mRNAs associated with PDGF BB signaling. Both obesity and idiopathic gastroparesis were also
associated with similar alterations in pathways associated with inflammation.
Conclusions: Our findings show that obesity and idiopathic gastroparesis result in overlapping but distinct changes in
the gastric muscularis transcriptome. Increased expression of mRNAs encoding smooth muscle contractile proteins may
be contributing to the increased gastric motility observed in obese subjects, whereas decreased PDGF BB signaling may
be contributing to the impaired motility seen in subjects with idiopathic gastroparesis.
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Background
Gastroparesis defined as delayed gastric emptying in the
absence of a physical obstruction, is estimated to occur
in about 1.8% of the adult population, with the majority
of cases being in women [1, 2]. Patients with gastropar-
esis have a marked decrease in their quality of life, with
symptoms including nausea, vomiting, early satiety,
bloating and abdominal pain. As gastric emptying is
dependent on an intricate interaction of neural cells,
interstitial cells of Cajal (ICC), platelet derived growth
factor α positive (PDGFRα+) fibroblasts and smooth
muscle cells (SMCs), it is likely that defects in any of
these cell types can contribute to this disease [3–7]. ICC
are the pacemaker cells in the stomach that transmit
slow wave depolarization to the gastric smooth muscle
cells [5, 8]. The PDGFRα+ fibroblasts are a more recently
recognized component of the electrical syncytium that
controls gastric contractility. These cells transmit inhibi-
tory neural signals to gastric smooth muscle cells [3].
Using qRT-PCR of RNA isolated from the stomach mus-
cularis of control and gastroparesis patients we previ-
ously reported that idiopathic gastroparesis is associated
with altered smooth muscle cell contractile protein ex-
pression and loss of PDGFRα+ cells without a change in
ICC [9]. Recently global transcriptional profiling sug-
gested that innate immune signaling may play a central
role in the pathogenesis of gastroparesis [10]. These ob-
servations are consistent with rodent studies that have
shown a critical role of macrophages in the pathogenesis
of gastroparesis [11, 12].
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In our recent studies, and in other studies published
by the NIDDK Gastroparesis Clinical Research Consor-
tium, control biopsies have been obtained from patients
undergoing bariatric weight loss surgery [4, 9, 13–15].
Although these patients provide ready access to control
biopsies that can be collected from the same region of
the stomach, and in the same manner as the samples
from gastroparesis patients, these subjects have the com-
plication of being obese. For example, in our recent
study the mean BMI of the control subjects was 47.8 ±
8.9 compared to 25.1 ± 6.9 in the gastroparetic group
[9]. Although the effects of obesity on gastric emptying
are somewhat controversial a large cohort study of 328
individuals demonstrated that obese subjects (BMI > 30
kg/m2) have increased rates of gastric emptying as com-
pared to low BMI subjects (BMI 18-25 kg/m2) [16, 17].
This increased gastric emptying in obese subjects raises
the possibility that some of the molecular and cellular
changes reported in patients with gastroparesis and de-
layed gastric emptying may be due to alterations in the
obese control group rather than a consequence of gas-
troparesis itself. This has long been recognized as a limi-
tation of previous gastroparesis studies. To attempt to
address this limitation a preliminary analysis of histo-
logical data from obese control subjects and non-obese
subjects undergoing surgery for gastroesophageal junc-
tion cancer suggested that obesity did not influence the
numbers of ICC observed in muscle biopsies [13]. How-
ever, there has not been a comprehensive study per-
formed to determine if other alterations that may occur
as a result of obesity may be complicating the interpret-
ation of changes observed in non-obese subjects with
gastroparesis. This was thus the goal of the current
study, in which we performed global transcriptional pro-
filing of gastric muscularis obtained from control sub-
jects with low BMI (organ donors) and from control
subjects with high BMI (undergoing bariatric surgery).
These data were then compared to data obtained from
subjects with idiopathic gastroparesis who had either
low (< 30) BMI or high BMI (> 30) in order to identify
transcriptional changes that occur as a result of idio-
pathic gastroparesis and to separate these changes from
those that occur as a result of obesity.
Methods
Clinical assessment
All procedures were conducted under protocol ap-
proved by the Indiana University Institutional Review
Board. Informed consents were obtained from control
subjects and patients with idiopathic gastroparesis.
Idiopathic gastroparesis was defined as patients with
symptoms of gastroparesis ≥3 months with delayed
gastric emptying by 4-h gastric scintigraphy or the
presence of a gastric bezoar with undigested foods by
upper endoscopy after an overnight fast. Gastric scin-
tigraphy was performed following consumption of a
low-fat egg-white meal with imaging at 0, 2 and 4 h
as described previously [18, 19]. Abnormal gastric
emptying was defined as 2-h retention ≥60% or 4-h
retention ≥10%. Gastroparesis patients included in the
study did not have diabetes as determined by normal
fasting glucose or normal hemoglobin A1c (HbA1c)
by blood test. We also excluded subjects with other
systemic diseases such as surgery with vagal trauma,
scleroderma, mixed connective tissue disorder and
paraneoplastic syndrome.
Full-thickness stomach biopsies
Biopsies from the low BMI control group (no reported
diabetes or gastroparesis) were obtained from organ
transplant donors at the time of organ transplant. Biop-
sies from the high BMI control group were obtained
from non-diabetic individuals without gastroparesis
symptoms that were undergoing bariatric weight loss
surgery (normal HbA1c level < 1 month prior to surgery)
. Surgical full-thickness biopsies from the idiopathic gas-
troparesis patients were obtained at the time of routine
pathological analysis in patients with severe symptoms
or at the time of gastric stimulator placement. In each
case (controls and gastroparesis patients), the biopsy was
taken about 10 cm from the pylorus on the anterior as-
pect midway between the greater and lesser curvatures
of the stomach. All biopsies were obtained using linear
cutting staplers. For sleeve gastrectomy subjects the
sample was obtained after the stomach was removed
from the abdomen, for all other subjects the samples
were obtained laparoscopically. Tissues were collected
into ice cold DMEM (Dullbeco’s modified eagle media)
or RNAlater (Ambion) and immediately transferred to
the investigator’s laboratory. Both the submucosal and
mucosal layers were carefully removed from the muscu-
laris by dissection under a binocular microscope, the
muscularis was then flash frozen in liquid nitrogen and
ground to a powder under liquid nitrogen prior to stor-
age at − 80°. A small amount of frozen muscle tissue
powder (~ 150 mg) was homogenized in Trizol (Invitro-
gen) and a Purelink Micro RNA isolation kit was used to
isolate total RNA. Contaminating DNA was removed by
on-column DNase treatment. The integrity and purity of
the isolated RNA was determined using an Agilent Bioa-
nalyzer. Samples used had an RNA integrity number of
> 7. Levels of ATP4A and gastrin mRNA were analyzed
in all samples by qRT-PCR to screen for mucosal con-
tamination. Only samples which had levels of expression
of these markers that were less than 100-fold lower than
the levels present in mucosa were utilized for further
analysis.
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Library preparation and sequencing
The concentration and quality of total RNA samples was
first assessed using Agilent 2100 Bioanalyzer. A RIN
(RNA Integrity Number) of 7 or higher was required to
pass the quality control. Then 200 ng of RNA per sample
was used to prepare a dual-indexed strand-specific cDNA
library using KAPA mRNA Hyperprep Kit (Roche). The
resulting libraries were assessed for their quantity and size
distribution using Qubit and Agilent 2100 Bioanalyzer.
Two hundred pico molar pooled libraries were utilized
per flowcell for clustering amplification on cBot using
HiSeq 3000/4000 PE Cluster Kit and sequenced with 2.75
bp paired-end configuration on HiSeq4000 (Illumina)
using HiSeq 3000/4000 PE SBS Kit. A Phred quality score
(Q score) was used to measure the quality of sequencing.
More than 90% of the sequencing reads reached Q30
(99.9% base call accuracy). The sequencing was performed
in the Center for Medical Genomics (CMG) at Indiana
University School of Medicine, a sequencing core facility
of the Indiana CTSI.
Sequence alignment and gene counts
The sequencing data were first assessed using FastQC
(Babraham Bioinformatics, Cambridge, UK) for quality
control. Then all sequenced libraries were mapped to
the human genome (UCSC hg38) using STAR RNA-seq
aligner [20] with the following parameter: “--outSAM-
mapqUnique 60”. The reads distribution across the gen-
ome was assessed using bamutils (from ngsutils) [21].
Uniquely mapped sequencing reads were assigned to
hg38 refGene genes using featureCounts (from subread)
with the following parameters: “-s 2 –p –Q 10” [22].
Quality control of sequencing and mapping results was
summarized using MultiQC [23]. Genes with read count
per million (CPM) > 0.5 in more than 4 of the samples
were kept. The data was normalized using TMM
(trimmed mean of M values) method. The median num-
ber of uniquely mapped reads obtained per sample were
28.7 million (86.96% of raw reads) with a minimum of
22.3 million and a maximum of 32 million. Differential
expression analysis was performed using edgeR [24, 25].
False discovery rate (FDR) was computed from p-values
using the Benjamini-Hochberg procedure. Complete
RNA-sequencing data is available from the NCBI GEO
database, accession number GSE129398.
qRT-PCR. 500 ng of RNA was used in reverse tran-
scription reactions (High Capacity RT-cDNA Kit, Life
Technologies). Real time PCR was performed using Sybr
Green (Roche). Levels of mRNA expression were nor-
malized to expression of TATA binding protein (TBP) as
an internal control and are expressed relative to the
mean values seen in samples from control low BMI pa-
tients. The primers used for qRT-PCR are listed in Add-
itional file 4: Table S1
Statistical analysis
Significant differences between groups were identified
using one way Anova analysis with a Kruskal-Wallis test
and a Duns Multiple Comparison post-test.
Results
Obese subjects have elevated ICC markers but no change
in markers of PDGFRα positive fibroblasts compared to
low BMI subjects
To determine if obesity is affecting the transcriptome of
the stomach muscularis externa we obtained full thick-
ness biopsy samples from transplant donors at the time
of organ harvest and reevaluated the previously reported
mRNA changes described in idiopathic gastroparesis
subjects [9]. Tissues were obtained from low BMI con-
trol donors (Mean BMI 24.0 ± 2.8, mean age 34.8 ± 13, 4
female, 5 male, n = 9), high BMI control bariatric surgery
patients (Mean BMI 49.2 ± 10, mean age 43.7 ± 7.5, 8 fe-
male, 2 male, n = 10) and low BMI subjects with idio-
pathic gastroparesis (mean BMI 23.2 ± 3.8, mean age
35.5 ± 10.6, 11 female, 2 male n = 13). The clinical data
of the subjects used are summarized in Additional file 5:
Table S2 Previous immune-histological studies have sug-
gested that ICCs are decreased in patients with idio-
pathic gastroparesis [4, 13]. However, we did not
observe any changes in mRNA encoding the ICC
markers KIT or ANO1 in our previous study, although
we did observed decreased expression of PDGFRα and
PDGFB mRNA and in mRNAs encoding several smooth
muscle contractile proteins [9]. We thus reevaluated
these findings utilizing samples from low BMI transplant
donors as controls. This analysis revealed that the ICC
markers KIT and ANO1 were significantly higher in the
muscularis of control subjects with high BMI as com-
pared to those with low BMI (Fig. 1a). KIT mRNA was
also significantly higher in idiopathic gastroparesis sub-
jects with low BMI, compared to the low BMI control
patients. Consistent with our previous studies there was
no significant difference in these mRNAs between the
high BMI control subjects and the idiopathic gastropar-
esis patients. In contrast to KIT and ANO1 mRNA ex-
pression, PDGFRα and PDGFB mRNAs were not
significantly changed in high BMI control subjects as
compared to the low BMI control subjects (Fig. 1b).
However, these mRNAs were significantly decreased
in the low BMI gastroparesis subjects compared to
the low BMI control subjects or high BMI control
subjects (Fig. 1b).
mRNAs encoding some smooth muscle contractile
proteins were elevated both in obese subjects and in
subjects with gastroparesis
In contrast to our previously reported decreases in expres-
sion of mRNAs encoding some contractile proteins in
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idiopathic gastroparesis subjects compared to high BMI
control subjects [9], when compared to low BMI transplant
donor controls, idiopathic gastroparesis subjects had ele-
vated levels of mRNAs encoding MYH11, ACTA2 and
MYLK1 (Fig. 2). Interestingly MYH11, MYLK1 and ACTA
G2 mRNAs were also significantly elevated in high BMI
control subjects compared to low BMI control subjects, this
was accompanied by a significant elevation in SRF mRNA
(Fig. 2). This elevation in the high BMI control group could
account for our previous finding of decreased expression of
these mRNAs in idiopathic gastroparesis subjects as com-
pared to high BMI control subjects [9].
Obesity and gastroparesis are associated with distinct but
overlapping gastric muscularis transcriptomes
Together, the data described above, suggest that obesity
has a significant impact on mRNA expression in the
stomach muscularis. These findings may significantly
alter the interpretation of previous data that utilized
tissues obtained from obese patients as controls. For ex-
ample, increased expression of mRNAs in stomach mus-
cularis of obese subjects may result in an apparent
decrease in these mRNAs in gastroparesis subjects when
in fact they may be unchanged or increased compared to
low BMI control subjects. To evaluate this possibility
more fully we performed a whole transcriptome RNA-
sequencing analysis of the muscularis obtained from low
BMI control donors (Mean BMI 24.8 ± 3.3, mean age
38.5 ± 15.7, 3 female and 3 male, n = 6), high BMI con-
trol bariatric surgery patients (Mean BMI 51.9 ± 11.5,
mean age 44.8 ± 8.9, 3 female and 3 male, n = 6) and low
or high BMI subjects with gastroparesis (mean BMI
24.2 ± 4.6, mean age 41 ± 7.9, all female, n = 6 and mean
BMI 36.6 ± 1.8, mean age 43 ± 17.9, 3 female and 1 male,
Fig. 1 Increased KIT and ANO1 mRNA in obese subjects, decreased PDGFRα and PDGFB mRNA in subjects with gastroparesis. Total RNA was isolated from the
muscle layer of biopsies obtained from 9 control subjects with low BMI, 10 control subjects with high BMI and 13 subjects with idiopathic gastroparesis and
low BMI. qRT-PCR was used to measure the expression of each of the mRNAs indicated. Data presented were normalized to an internal control encoding TBP
and are expressed relative to levels in the control low BMI subjects. Relative expression =2-ΔΔCt, where ΔΔCt = (CtHigh BMI or Gastroparesis-CtTBP) – (CtLow BMI control-
CtTBP). Each point represents an individual subject. The mean± SEM are also indicated. Significant differences between groups were identified using one-way
Anova analysis with a Kruskal-Wallis test and a Duns Multiple Comparison post-test
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Fig. 2 mRNAs indicative of contractile smooth muscle are elevated in the muscularis of obese subjects and in subjects with gastroparesis. Total
RNA was isolated from the muscle layer of biopsies obtained from 9 control subjects with low BMI, 10 control subjects with high BMI and 13
subjects with idiopathic gastroparesis and low BMI. qRT-PCR was used to measure the expression of each of the indicated mRNAs. Data presented were
normalized to an internal control encoding TBP and are expressed relative to levels in the control low BMI subjects. Relative expression =2-ΔΔCt, where
ΔΔCt = (CtHigh BMI or Gastroparesis-CtTBP) – (CtLow BMI control-CtTBP). Each point represents an individual subject. The mean ± SEM are also indicated. Significant
differences between groups were identified using one-way Anova analysis with a Kruskal-Wallis test and a Duns Multiple Comparison post-test
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n = 4, respectively). To visualize the overall differences
in mRNA expression between each of the groups of
samples we performed a heat map analysis on all genes
that were found to be significantly different between any
group of samples as determined by an ANOVA analysis
with an FDR cutoff of < 0.05. For the heat map analysis
sample grouping was assessed using a complete linkage
analysis together with a Pearson distance analysis (Heat-
mapper). This analysis clearly showed that the samples
obtained from control patients with a low BMI clustered
away from both the samples from control patients with
high BMI and the samples from subjects with idiopathic
gastroparesis (Fig. 3). Interestingly the high BMI control
samples clustered closer to the idiopathic gastroparesis
samples than the low BMI control samples. As expected
the samples obtained from control subjects with high
BMI were also distinct from those obtained from sub-
jects with gastroparesis regardless of the BMI of the gas-
troparesis subjects. Although the samples from high and
low BMI idiopathic gastroparesis subjects separated
from each other they were more similar to each other
than to either of the control groups (Fig. 3).
To begin to identify which changes in mRNA expres-
sion were associated with gastroparesis as opposed to
obesity we first compared differentially expressed genes
in each group as shown in Fig. 4. Differentially expressed
genes were analyzed in two different ways, in the first,
log2 fold changes were calculated on all samples relative
to the low BMI samples, the resultant gene sets were
then filtered to remove genes located on the Y chromo-
some. In a second approach samples were compared
only to other samples obtained from subjects of the
same gender (Additional file 6: Table S3) Differentially
expressed genes were then filtered to those exhibiting a
logFC of − 1 or less or of + 1 or greater with a FDR of <
0.05 (i.e. genes with a 2 or greater-fold change in expres-
sion). Within these data, we identified those genes
whose expression was altered irrespective of which
method of analysis we used (Y chromosome filtered or
gender based) and then compared those genes identified
in each group (Fig. 4). From this analysis, we identified
264 genes that were differentially expressed in the high
BMI control group compared to the low BMI control
group, 527 genes that were differentially expressed in
the low BMI gastroparesis group compared to the low
BMI control group and 567 genes that were differentially
expressed in the high BMI gastroparesis group com-
pared to the low BMI control group (> 2 fold, FDR <
0.05, Fig. 4). Ingenuity pathway analysis of each of these
groups of genes revealed a marked similarity in canon-
ical pathways affected with, granulocyte adhesion and
diapedesis, osteoarthritis and atherosclerosis signaling
being within the top 5 affected pathways shared between
all groups (Fig. 4). This finding is consistent with the
previously reported studies which reported immune dys-
regulation in human gastroparesis and the general idea
that obesity is associated with inflammation [10]. It is
however, important to note that the about two thirds of
the genes within these pathways that were significantly
changed were down-regulated rather than being upregu-
lated, in samples from obese patients and in samples
from patients with gastroparesis. Despite the similarities
in affected pathways in the obese and gastroparesis sub-
jects, Ingenuity analysis identified distinct potential up-
stream regulators that were affected in each group. For
example, PI3K was the most confidently predicted up-
stream regulator of genes in the high BMI control group
compared to the low BMI control group. Several of the
predicted PI3K target genes were further examined by
qRT-PCR, of these CXCL10 was found to be specifically
elevated in high BMI control subjects, whereas HMOX1
and SREBF1 were decreased both in high BMI control
subjects and in low BMI subjects with idiopathic gastro-
paresis (Additional file 1: Figure S1). In contrast, PDGF
BB and TREM1 were the most significant predicted up-
stream regulators of the idiopathic gastroparesis groups.
As our initial qRT-PCR analysis revealed decreased
PDGFRα and PDGFB in gastroparesis subjects (Fig. 1b)
we further validated a number of the mRNAs predicted
to be regulated by PDGF BB (Additional file 7: Table S4)
This analysis confirmed the downregulation of almost all
the predicted PDGF BB targets that we examined and
revealed that these changes were specific to the idio-
pathic gastroparesis subjects as none of these target
genes were significantly affected by obesity (Fig. 5).
In light of the similarities in canonical pathways
affected in each of our groups of subjects we further in-
vestigated the overlap of the genes that were significantly
altered in each group. The Venn diagram shown in Fig. 6
illustrates the overlaps between the genes whose expres-
sion were significantly different in samples from high
BMI control subjects and low or high BMI subjects with
gastroparesis as compared to the low BMI control sub-
jects. We compiled 9 lists of differentially expressed
genes representing the genes in each segment of the
Venn diagram (Additional file 8: Table S5) Ingenuity
pathway analysis was then performed on each of these
gene lists to identify the canonical pathways, upstream
activators and diseases that were enriched in each group
(Fig. 6). From this analysis, we noted that the mRNAs
that were differentially expressed in the high BMI con-
trol samples but not affected by gastroparesis (55
mRNAs) were significantly related to diabetic neur-
opathy, diabetes and obesity as might be anticipated
(HiC not in LoG or HiG; Fig. 6). Of the mRNAs altered
in the gastroparesis groups that were not also altered
in the high BMI control group only 151 were shared
between the high and low BMI gastroparesis groups,
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whereas 239 were unique to the high BMI gastropar-
esis group and 206 unique to the low BMI gastropar-
esis group (Fig. 6). These three groups of mRNAs
combined were enriched for pathways associated with
granulocyte and agranulocyte adhesion and diapedesis,
osteoarthritis and atherosclerosis (HiG or LoG not in
HiC; Fig. 6). This group was also enriched for the up-
stream activators PDGF BB and TREM1 and the
diseases, breast, pancreatic or ovarian cancer and
seizure disorders. These observations are consistent
with the findings that many PDGF BB target genes
are uniquely affect by gastroparesis but not obesity
(Fig. 5).
Pathway analysis of the 209 mRNAs shared between the
high BMI control group and either the low or high BMI gas-
troparesis groups revealed an enrichment in pathways
Fig. 3 Heatmap linkage analysis illustrates distinct differences in the transcriptome in control, obese and gastroparesis subjects. To visualize the
overall differences in mRNA expression between each of the groups of samples used for RNA sequencing we performed a heat map analysis on
all genes that were found to be significantly different between any group of samples as determined by an ANOVA analysis with an FDR cutoff of
< 0.05. Expression data were exported from edgeR software and average log2-counts-per-million were imported into Heatmapper (www.heatmapper.ca).
For the heat map analysis sample grouping was assessed using a complete linkage analysis together with a Pearson distance analysis. LoC- low BMI
control, HiC-high BMI control, LoG- low BMI gastroparesis, HiG-high BMI gastroparesis
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associated with LXR/RXR activation in addition to those as-
sociated with granulocyte adhesion and diapedesis, athero-
sclerosis and osteoarthritis (HiC and HiG or LoG; Fig. 6).
Interestingly the most enriched upstream activator in this
group was SP1. As obesity has been reported to be associated
with an increased rate of gastric emptying as compared to
the decreased gastric emptying characteristic of gastroparesis
we hypothesized that if genes within this shared group are
related to gastric emptying then they may be oppositely af-
fected in the obesity and gastroparesis subjects. However, we
found that almost all of genes within this shared group were
similarly affected by both obesity and gastroparesis suggest-
ing that they are not likely to be directly related to gastric
emptying (Fig. 7).
Transcriptome changes associated with gastroparesis
irrespective of the BMI of control subjects
A recent study reported results of a similar transcrip-
tome wide analysis of changes in gene expression in the
stomach of gastroparesis patients [10]. There are two
major differences between this published study and the
current study. Firstly, we utilized muscularis which was
dissected free from mucosa and submucosa from full
thickness biopsies to harvest RNA for our analysis
whereas in the previous study the mucosa was simply
peeled from the biopsy. Secondly, we utilized low BMI
transplant donors as our control group whereas the pre-
vious study utilized subjects undergoing bariatric surgery
and therefore presumably with high BMIs. To better
Fig. 4 Pathway analysis of differentially expressed genes. Genes differentially expressed between either the high BMI control group (HiC) or the
low (LoG) or high (HiG) BMI gastroparesis groups and the low BMI control group (LoC) were analyzed in two different ways. In the first, log2 fold
changes were calculated on all samples relative to the low BMI samples, the resultant gene sets were then filtered to remove genes located on
the Y chromosome. In a second approach samples were compared only to other samples obtained from subjects of the same gender (Additional
file 6 : Table S3). Differentially expressed genes were then filtered to those exhibiting a logFC of − 1 or less or of + 1 or greater with a FDR of <
0.05 (i.e. genes with a 2 or greater fold change in expression). A comparison analysis was then performed to identify those genes whose change
in expression was significant no matter which analysis was performed. These lists of genes were then subject to Ingenuity pathway analysis. The
resultant top 5 canonical pathways, upstream regulators and diseases are shown
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compare the findings of the two studies we reanalyzed
our data without separating the low and high BMI gas-
troparesis groups from each other (CombG group in
Additional file 2: Figure S2; Additional file 9: Table S6)
We then compared the differentially expressed genes
(relative to the low BMI controls) identified in our
Fig. 5 Predicted PDGF BB regulated genes are downregulated in gastroparesis subjects. Consistent with the qRT-PCR data shown in Fig. 1b,
Ingenuity pathway analysis revealed that PDGF BB signaling may be altered in subjects with gastroparesis (Fig. 4 and Additional file 7: Table S4).
Total RNA was isolated from the muscle layer of biopsies obtained from 9 control subjects with low BMI, 10 control subjects with high BMI and
13 subjects with idiopathic gastroparesis and low BMI. qRT-PCR was used to verify some of these changes in PDGF BB dependent mRNAs. Data
presented were normalized to an internal control encoding TBP and are expressed relative to levels in the control low BMI subjects. Relative
expression =2-ΔΔCt, where ΔΔCt = (CtHigh BMI or Gastroparesis-CtTBP) – (CtLow BMI control-CtTBP). Each point represents an individual subject. The mean ±
SEM are also indicated. Significant differences between groups were identified using one-way Anova analysis with a Kruskal-Wallis test and a
Duns Multiple Comparison post-test
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Fig. 6 Comparison of the changes in mRNA expression in each of the subject groups. Comparison analysis and pathway analysis were performed
using Ingenuity Pathway Analysis software. The Venn Diagram shown illustrates the numbers of mRNAs whose expression are altered 2-fold or
more (FDR < 0.05) in the control subjects with high BMI (HiC) or in the gastroparesis subjects with low (LoG) or high BMI (HiG) as compared to
low BMI control subjects (LoC). Ingenuity pathway analysis was performed on each of the indicted groups of genes from each segment of the
Venn diagram and the top 5 canonical pathways, upstream regulators and diseases are indicated
Fig. 7 Both obesity and gastroparesis have similar effects on a core group of genes. Relative changes in expression of the common set of mRNAs
whose expression was significantly altered in control subjects with high BMI (HiC) and in gastroparesis subjects with low(LoG) or high BMI (HiG)
are indicated (The, LoG and HiG and HiC group of 138 genes shown in Fig. 6)
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CombG group, to the differentially expressed genes in
the high BMI control group and those identified in the
idiopathic gastroparesis group of the previous published
study (Grover; Additional file 2: Figure S2). Of the 657
differentially expressed genes in the CombG group only
157 were also identified in the previous study and 41 of
these were also differentially expressed in the high BMI
control group (HiC, CombG and Grover group; Add-
itional file 2: Figure S2). Pathway analysis of the 116
mRNAs that were shared between the CombG group
and the previous study but not in the high BMI control
group revealed an enrichment in pathways associated
with coagulation, the role of macrophages, fibroblasts
and endothelial cells in rheumatoid arthritis, granulocyte
adhesion and diapedesis and atherosclerosis (Grover and
CombG not in HiC group; Additional file 2: Figure S2).
PDGF BB was again identified as the most enriched up-
stream activator of this group consequently many of the
most differentially expressed genes are predicted PDGF
BB targets and have been verified in Fig. 5. We further
validated changes in 6 additional mRNAs within this
group by qRT-PCR (Additional file 3: Figure S3). Sur-
prisingly this analysis failed to validate the most highly
upregulated gene in this group, PRKG2. It might be pre-
dicted that the 360 genes whose expression was altered
in the published idiopathic gastroparesis cohort but not
altered in either our high BMI controls or our idiopathic
gastroparesis subjects may represent genes that are
changed selectively in the submucosa as this was not
rigorously removed in the biopsies used in the previous
study (Grover not HiC or CombG group; Additional file
2: Figure S2). Pathway analysis of these genes revealed
an enrichment in genes associated with Th1/Th2 activa-
tion, phagosome formation, B cell receptor signaling and
CD28 signaling (Grover not in HiC or CombG; Add-
itional file 2: Figure S2). Predicted enriched upstream ac-
tivators of this group include TNF, PDGF BB and IL2
and disease processes associated with this group include,
cell movement, activation of cells, activation of blood
cells, leukopoiesis and binding of blood cells (Additional
file 2: Figure S2).
Discussion
The results of our study show that obesity results in
changes in mRNA expression in the gastric muscularis
that reflects increased expression of markers of ICC and
smooth muscle cells and a general decrease in expres-
sion of genes associated with inflammation (Figs. 1 and
2). We also observed an increase in mRNAs encoding
contractile proteins in the gastric muscularis of subjects
with idiopathic gastroparesis and confirmed our previ-
ously reported decreases in mRNAs associated with
PDGFRα-positive fibroblasts in these subjects (Figs. 1
and 2). Altered PDGF BB signaling was further
suggested from our RNA-sequencing analysis which re-
vealed PDGF BB as a predicted upstream regulator of
many of the mRNAs whose expression were specifically
decreased in idiopathic gastroparesis subjects (Figs. 4
and 6, Additional file 7: Table S4).
Immuno-histological studies have suggested that num-
bers of ICC are decreased in patients with idiopathic
and diabetic gastroparesis [13, 14, 26] However, our pre-
vious quantitative RT-PCR analysis failed to detect any
changes in mRNAs characteristic of ICC (KIT, ANO1)
[9]. The current study suggests that the control samples
used in all the previous studies which were obtained
from subjects undergoing bariatric surgery may actually
have increased expression of mRNAs characteristic of
ICC compared to control subjects with a low BMI (Fig.
1a). This may suggest that the reported decreases in ICC
in idiopathic gastroparesis subjects may actually reflect
an increase of ICC in the high BMI control subjects rela-
tive to the generally low BMI idiopathic gastroparesis
subjects. However, not consistent with this interpretation
is our previous and current study in which we did not
detect any significant differences in expression of KIT,
ANO1 or KITLG between the high BMI control subjects
and the low BMI idiopathic gastroparesis subjects.
Moreover, there was a significant increase in KIT mRNA
expression in the idiopathic gastroparesis subjects com-
pared to the low BMI control subjects. Together our
data would suggest that as both obesity and idiopathic
gastroparesis result in increased KIT mRNA expression
yet these two conditions have opposing effects on gastric
emptying, changes in KIT mRNA expression do not cor-
relate with changes in gastric emptying. A limitation of
our current and previous studies is that we are using
changes in mRNA expression to make inferences about
abundance of ICC cells, we did not directly measure
ICC abundance, additionally protein levels of these ICC
markers may not directly reflect mRNA levels. Con-
versely, the previous immune-histological studies mea-
sured numbers of ICC based on the number of KIT
positive cells but did not directly measure overall KIT
expression. How changes in ICC number or mRNA/pro-
tein expression affect overall ICC function and pace-
maker activity will be an important question to unravel
in order to fully elucidate the role of ICC in idiopathic
gastroparesis.
We previously reported decreases in mRNAs encoding
smooth muscle contractile proteins in the gastric mus-
cularis of subjects with idiopathic gastroparesis as com-
pared to high BMI control subjects [9]. However, when
compared to control subjects with low BMI, mRNAs en-
coding contractile proteins were not decreased in low
BMI idiopathic gastroparesis subjects and in fact several
were significantly increased (Fig. 2). These mRNAs were
also increased in the high BMI control subjects relative
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to the low BMI control subjects (Fig. 2). As obesity may
be associated with increased gastric emptying [16, 17],
the increased expression of mRNAs encoding smooth
muscle contractile proteins could contribute to
increased gastric motility in obese subjects. These in-
creases in mRNAs encoding smooth muscle contractile
proteins were also associated with increased expression
of serum response factor (SRF) mRNA, a key transcrip-
tion factor that regulates expression of many of these
genes. In contrast, it is clear that increased expression of
contractile proteins in idiopathic gastroparesis subjects
is not likely to be resulting in impaired gastric emptying.
The reason behind the increases in several of these
mRNAs encoding contractile proteins in the idiopathic
gastroparesis subjects is not so obvious. One possible ex-
planation could be that this represents a compensatory
mechanism that is activated in order to try to increase
motility in subjects with impaired gastric emptying. This
would be a very difficult mechanism to test in humans
as it would be necessary to obtain biopsies from gastro-
paresis subjects early in the progression of their disease
prior to the initiation of compensatory mechanisms,
which is not clinically feasible.
Although we observed that obesity has significant
effects on the mRNAs characteristic of ICC and smooth
muscle cells it did not affect expression of the three
mRNAs we examined that would be characteristic of
PDGFRα -positive fibroblasts (Fig. 1b). Both PDGFRα
and PDGFB were downregulated in idiopathic gastropar-
esis subjects relative to low BMI control subjects,
whereas their expression was not significantly different
between low and high BMI control subjects. Decreased
PDGF BB signaling in idiopathic gastroparesis subjects
was also suggested by upstream activator analysis of
RNA-sequencing data and subsequent qRT-PCR con-
firmation (Figs. 4 and 6, Additional file 7: Table S4) This
analysis further confirmed that these changes were spe-
cific to the idiopathic gastroparesis and were not also in-
duced by obesity alone. Together these data provide a
strong argument that decreased PDGF BB signaling may
be associated with the pathogenesis of idiopathic gastro-
paresis. However, this must be interpreted within the
limitations of our study. We have not directly measured
PDGF BB signaling but rather analyzed expression of
predicted target genes as a surrogate, and all these target
genes are also regulated by other signaling pathways.
From our studies, it is also not possible to determine if
the predicted impairment in PDGF BB signaling is re-
stricted to the PDGFRα-positive fibroblasts or if it also
occurs in other cell types, as PDGF BB can also signal
through PDGFRB which is expressed on other cells, in-
cluding gastric smooth muscle cells [27]. Despite these
limitations, given the known impact of PDGF BB on
smooth muscle cell proliferation together with the
importance of PDGFRα-positive fibroblasts in inhibitory
neuromuscular transmission and the fact that many of
the target genes we confirmed as being decreased are re-
lated to proliferation it is not unreasonable to propose
that decreased PDGF BB signaling may be contributing
to the pathogenesis of idiopathic gastroparesis.
Extensive data from rodent models and in vitro studies
support the proposal that altered macrophage
polarization plays a critical role in the pathogenesis of
gastroparesis [11, 12, 28]. Recent human studies further
support this model in showing that there is an increased
percentage of mRNAs related to M1 macrophages in
subjects with idiopathic gastroparesis [10]. The majority
of the canonical pathways affected by gastroparesis in
the current study were also related to inflammation.
However, we noted that many of the genes in these path-
ways were downregulated. Closer examination of these
genes revealed that they represent both proinflammatory
cytokines and receptors such as IL1B, IL1R1/2, CCL2,
SPP1 and ICAM as well as inhibitory molecules such as
IL1RN and SOCS3. Surprisingly, similar decreases in in-
flammation related genes were observed in the gastric
muscularis of obese subjects. This was unexpected as
obesity is generally known to be an inflammatory state.
Again, however, the decreases in mRNAs encoding both
pro- and anti-inflammatory cytokines prevent us from
determining if there is an overall increase or decrease in
inflammation in the gastric muscularis. The decrease in
HMOX1 which encodes heme-oxidase 1 an enzyme
expressed in M2 macrophages that helps protect against
oxidative stress would be consistent with previous stud-
ies suggesting an increase in the M1/M2 macrophage ra-
tio in gastroparesis. (Additional file 1: Figure S1) [10, 28,
29] We attempted to further interrogate the inflamma-
tory cell changes using Cibersort [30], however, none of
our samples had significant P values in this analysis pre-
venting us from drawing any meaningful conclusions
from the data. We hypothesize that this may be due to
the relatively low abundance of inflammatory cells in
our samples, as a result of the removal of the mucosa
and submucosa from our biopsies which would be where
most of the immune cells would be expected to be lo-
cated. Consistent with this idea is our observation that
the group of mRNAs identified in the previous study by
Grover et al. that were not significantly altered in our
idiopathic gastroparesis subjects, and therefore may rep-
resent mRNAs from the submucosa, were enriched for
immune signaling pathways (Th1/Th2 activation, phago-
some formation, B cell receptor signaling and CD28
signaling, Additional file 2: Figure S2) [10].
Our overall approach of identifying mRNAs whose ex-
pression are altered in idiopathic gastroparesis irrespect-
ive of the BMI of the gastroparesis subjects should
identify changes that are most commonly associated
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with the disease and thus most likely to be related to its
underlying pathophysiology. Use of Ingenuity pathway
analysis to identify pathways associated with the changes
in mRNA expression may, however, introduce some bias
in the identified pathways as a result of an overabun-
dance of molecules linked to cancer and inflammation
in the Ingenuity database. The approach we used also
has the limitation in that it does not permit the identifi-
cation of molecules or pathways that are crucial to the
pathophysiology of gastroparesis in only individual sub-
jects or subgroups of subjects. In addition, the relatively
small sample size used in both the qRT-PCR analysis
and the RNA-sequencing analysis limits the detection of
relatively small gene expression changes that may also
be further masked by unknown comorbidities in the pa-
tients. A much more extensive analysis, using a far
greater number of gastroparesis subjects will be required
to determine if there are subgroups of subjects that have
shared transcriptional changes, which could account for
the unique clinical manifestations of their disease.
Conclusions
Results from our study suggest that it may be better to
utilize BMI matched control subjects when investigating
pathological changes that occur during idiopathic gastro-
paresis. Data suggest that obesity alone may be inducing
changes in the stomach muscularis that increase motility
and affect inflammation. Analysis suggest that altered
PDGF BB signaling may be acting together with dysfunc-
tional inflammatory pathways in the pathogenesis of
idiopathic gastroparesis.
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